BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform
New Zealand and Kingston, Ontario--(Newsfile Corp. - April 7, 2026) - BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), today announced the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon® automated cell therapy manufacturing platform. The collaboration builds upon the existing...
2026-04-07 10:15 AM EDT
Octane Medical Group Signs Agreement to Acquire Lonza's Personalized Medicine Business
Kingston, Ontario--(Newsfile Corp. - March 4, 2026) - Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal that comprises Lonza's controlling stake in the Cocoon® Platform - originally acquired from Octane in 2018 - alongside associated intellectual property (IP), workforce and existing customer contracts. Completion of the transaction is subject...
2026-03-04 6:00 PM EST
Octane Medical Acquires B. Braun's Global Orthobiologics Business
Melsungen, Germany--(Newsfile Corp. - June 7, 2024) - Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine. The orthobiologics platform currently includ
2024-06-07 11:11 AM EDT